Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism

Fulvestrant (Faslodex™) is a pure antiestrogen that is effective in treating estrogen receptor-(ER) positive breast cancer tumors that are resistant to selective estrogen receptor modulators such as tamoxifen. Clinical trials investigating the utility of adding fulvestrant to other therapeutics have...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Edavana, Vineetha K, Penney, Rosalind B, Yao-Borengasser, Aiwei, Williams, Suzanne, Rogers, Lora, Dhakal, Ishwori B, Kadlubar, Susan
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2013
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3841332/
https://ncbi.nlm.nih.gov/pubmed/24298433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2193-1801-2-620
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi